Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
20 Dezembro 2023 - 9:00AM
Business Wire
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology and pharmaceutical company focused on novel therapies
for the treatment of glaucoma, corneal disorders and retinal
diseases, today announced that its management is scheduled to
participate in the 42nd Annual J.P. Morgan Healthcare Conference on
Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.
A live and archived webcast for these events, where applicable,
will be available in the Investors section of the Glaukos website
at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
and pharmaceutical company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012, and continues to develop a portfolio
of technologically distinct and leverageable platforms to support
ongoing pharmaceutical and medical device innovations. Products or
product candidates for each of these platforms are designed to
advance the standard of care through better treatment options
across the areas of glaucoma, corneal disorders and retinal
diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231220102589/en/
Chris Lewis Vice President, Investor Relations & Corporate
Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Glaukos (NYSE:GKOS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024